Other financial assets

 
Loans
associates and joint ventures
Other
participations
Other
receivables
Other
deferred
items
Total
      
Balance at 1 January 2016
228
51
113
27
419
      
Changes:
     
- Charged to the income statement
-
(9)
3
(6)
(12)
- Capital payments
-
3
-
-
3
- Disposals
-
(3)
2
-
(1)
- Loans granted
31
-
-
-
31
- Repayments
-
-
(4)
2
(2)
- Consolidation changes
-
-
-
-
-
- Exchange differences
3
-
5
1
9
- Transfers
(8)
-
33
(2)
23
- Changes in fair value
-
7
-
-
7
- Other
(1)
1
(16)
2
(14)
      
Balance at 31 December 2016
253
50
136
24
463
      
Changes:
     
- Charged to the income statement
12
(8)
31
(6)
29
- Acquisitions
-
7
18
2
27
- Capital payments
-
47
-
-
47
- Disposals
-
(3)
-
-
(3)
- Loans granted / prepayments
-
-
49
-
49
- Repayments
(65)
-
(47)
-
(112)
- Consolidation changes
(2)
-
-
-
(2)
- Exchange differences
(4)
(4)
(9)
(1)
(18)
- Transfers
(1)
1
(2)
-
(2)
- Changes in fair value
-
(1)
-
-
(1)
- Other
-
-
1
(3)
(2)
      
Balance at 31 December 2017
193
89
177
16
475

For Loans associates and joint ventures, see also Note 10 'Associates and joint ventures'.

Other participations relate to equity instruments in companies whose activities support DSM's business and which can be quoted or unquoted. An amount of €42 million included in Other participations relate to equity instruments measured at cost (2016: €26 million).

In 2017, DSM made an equity investment in Amyris, Inc., an industrial bioscience company in the US for an amount of €34 million, which is included under Capital payments.

Repayments of €47 million in Other receivables include the settlement of € 32 million relating to the earn-out receivable of Patheon. See also Note 10 'Associates and joint ventures'.